• 18.12.2019 – 14:07

  Grünenthal Group

  Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

  Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

  more

• 28.06.2019 – 12:20

  Sympatex Technologies GmbH

  

  New laboratory study reveals that highly-toxic hydrofluoric and hydrochloric acids are released when PTFE burns

  more

• 14.11.2018 – 13:00

  Averitas Pharma

  Averitas Pharma commercializes Qutenza® in the US

  Morristown, New Jersey (ots) - Averitas Pharma, a recently acquired Grünenthal Group company, announced that it has taken over the US commercialization of Qutenza® (capsaicin) 8% patch on October 30, after the acquisition of the product by Grünenthal on the same day. Qutenza® is approved in the US for the management of neuropathic pain associated with postherpetic neuralgia. A single, 1-hour, localized treatment with ...

  more